The FDA has approved the first COPD biomarker for use in interventional clinical trials. The blood biomarker plasma fibrinogen can now be used in studies that examine exacerbations and/or all-cause mortality in patients with COPD, the regulatory body said in a statement. The initial biomarkers selected were plasma fibrinogen, St. George’s Respiratory Questionnaire, and the 6-minute walk test. ...
Already a member?
Enter your email to keep reading.